NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care diagnostics that help patients and physicians better manage chronic pain, nerve disorders, and associated sleep disturbances. The Company is located in Waltham, Massachusetts. It was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996 by Shai Gozani, M.D., Ph.D., NeuroMetrix President and Chief Executive Officer. The Company is publicly traded (Nasdaq: NURO).
The Company has a major focus on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy and other forms of chronic pain such as fibromyalgia, post herpetic neuralgia (shingles), and conditions with both chronic pain and disturbed sleep such as restless leg syndrome. The company also markets the DPNCheck® device, which is a rapid, accurate, and quantitative point-of-care test for peripheral neuropathies such as diabetic neuropathy. This product is used to detect neuropathies at an early stage and to guide treatment.
The Company also markets the ADVANCE™ System, which is a comprehensive platform for the performance of traditional nerve conduction studies and invasive electromyography procedures. Over 2 million patients have been tested with ADVANCE and prior generation NeuroMetrix nerve conduction testing platforms.
The Company is a global leader in the integration of neurophysiology, bioelectronics, and biosignal analysis into wearable therapeutics and point-of-care devices. It invented the concept of point-of-care neurodiagnostic testing and built this market over the past 15 years. In addition to its long standing leadership in point-of-care nerve testing, the Company is now focused on developing novel wearable therapeutic devices that empower people with chronic pain and sleep disorders to regain a higher quality of life.